Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Polskie Archiwum Medycyny Wewnetrznej|December 20, 2003
[Renal tubular dysfunction in patients with rheumatoid arthritis starting with low dose of methotrexate]Piotr Wiland, Anna Wiela-Hojeńska, Jerzy Swierkot, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 19, 2015
Application of (1)H NMR-based serum metabolomic studies for monitoring female patients with rheumatoid arthritisAdam Zabek, Jerzy Swierkot, Anna Malak, et al.
Polskie Archiwum Medycyny Wewnetrznej|December 20, 2003
[The role of diagnostic tests in the identification of Chlamydia trachomatis infection in reactive arthritis]Jerzy Swierkot, Irena Choroszy-Król, Katarzyna Marczyńska-Gruszecka, et al.
European Journal of Clinical Investigation|June 23, 2017
The role of microRNA-5196 in the pathogenesis of systemic sclerosisMarzena Ciechomska, Patryk Zarecki, Michal Merdas, et al.
Archivum Immunologiae Et Therapiae Experimentalis|May 11, 2018
Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis PatientsMarzena Ciechomska, Krzysztof Bonek, Michal Merdas, et al.
Joint Bone Spine|October 15, 2014
Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritisJerzy Swierkot, Katarzyna Bogunia-Kubik, Beata Nowak, et al.
International Journal of Molecular Sciences|July 24, 2021
Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and SpondyloarthropathiesKatarzyna Bogunia-Kubik, Wojciech Wojtowicz, Jerzy Swierkot, et al.
Rheumatology International|November 14, 2013
Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvementAgata Kosmaczewska, Jerzy Swierkot, Lidia Ciszak, et al.
RMD Open|February 5, 2022
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE studyRoy Fleischmann, Eduardo Mysler, Louis Bessette, et al.
RMD Open|May 28, 2024
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE studyRoy Fleischmann, Jerzy Swierkot, Sara K Penn, et al.
Pageof 4